Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
BOJ Seen Holding Rates at 1% While Keeping Inflation Risk Warning 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
Japan’s Nikkei Slides Over 2% as Alphabet Selloff Sparks AI Spending Concerns 
Oil Prices Head for Weekly Surge as Red Sea Attacks and Kazakhstan Supply Cuts Raise Disruption Fears 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
India FMCG Q1 Earnings Preview: Higher Input Costs Likely to Weigh on Profit Margins 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
Nvidia Reveals 9.3% Stake in AI Cloud Firm Nebius Following $2 Billion Investment 
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
Asian Stocks Slide as Oil Tops $100, Middle East Conflict Fuels Inflation Fears 
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral 
LG Chem Ltd. has finally completed completes acquisition of AVEO Pharmaceuticals inc., and this was announced last week. The South Korean chemical firm is aiming to become one of the top 30 pharma companies in the world, and the acquisition is the first step to achieving the goal.
LG Chem invested around $571 million in its LG Chem Life Science Innovation Center in the United States for the takeover of the US-based firm. As per Yonhap News Agency, the deal was first announced in October 2022, and the following December, the U.S. antitrust watchdog handed its approval for the deal to go ahead.
AVEO Pharma’s board of directors proceeded to accept LG Chem's offer in the second week of January. Thus, the transaction was completed. With the completion, the American pharma firm is now listed as a second-tier subsidiary of LG Chem.
AVEO Pharmaceuticals was founded in 2002 and was listed on Nasdaq in 2010. Its sales reached KRW130 billion or about $105 million last year, and this year, it was predicted to earn KRW210 billion.
LG Chem revealed that since the company is already one of its affiliates, it will be transferring its anti-cancer drug business to AVEO. This is also a strategic move on LG Chem’s part as it is also aiming to boost its production in the U.S. Moreover, the Korean firm will be investing KRW2 trillion in the research and development (R&D) bio business by 2027 and will release at least four new drugs in markets overseas.
“The merger extends LG Chem Life Sciences’ commercial footprint to the U.S., diversifies our pipeline and advances our combined capabilities with AVEO, accelerating our ability to develop, commercialize and acquire world-class cancer therapies,” LG Chem Life Sciences president, Dr. Son Jeewoong, said in a press release. “We look forward to working closely with AVEO’s experienced and talented team as we welcome them to the LG Chem family.”
AVEO’s president and chief executive officer, Michael Bailey, added, “This transaction delivered significant value to our shareholders and AVEO is now positioned to benefit from the support and resources of LG Chem as we advance our mission of improving the lives of patients with cancer.”
